Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.53 |
| ▸ | BRD4 | O60885 | 6/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | ESRRA | P11474 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5784623 | 0.96 | MAOB (0.51) | MAOBCYP19A1BRD4PTGDR2MRGPRX4 | |
| SCHEMBL23226755 | 0.91 | CYP19A1 (0.54) | CYP19A1BRD4MRGPRX4F2F10 | |
| SCHEMBL11091209 | 0.89 | CYP19A1 (0.52) | CYP19A1BRD4ESRRAF2F10 | |
| SCHEMBL15754360 | 0.89 | SMN1; SMN2 (0.56) | CYP19A1BRD4MRGPRX4ESRRAF2 | |
| SCHEMBL6074797 | 0.88 | PTGDR2 (0.66) | MAOBCYP19A1BRD4PTGDR2MRGPRX4 | |
| SCHEMBL6074264 | 0.88 | CYP19A1 (0.51) | CYP19A1BRD4ESRRAF2F10 | |
| SCHEMBL11671517 | 0.87 | AR (0.52) | MAOBCYP19A1BRD4PTGDR2MRGPRX4 | |
| SCHEMBL1221632 | 0.87 | CYP19A1 (0.50) | CYP19A1BRD4ESRRAF2F10 | |
| SCHEMBL10659205 | 0.87 | CYP19A1 (0.50) | CYP19A1BRD4ESRRAF2F10 | |
| Water SCHEMBL10641992 | 0.86 | CYP19A1 (0.49) | CYP19A1BRD4ESRRAF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390668-A | Compound with ketoxime ether structure and application thereof | 复旦大学 | 2025-02-07 | — | — | CN | disclosed |
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | Academic Pharmaceuticals, Incorporated (US) | 2022-03-29 | — | — | US | disclosed |
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | Academic Pharmaceuticals, Incorporated (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210107867-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACADEMIC PHARMACEUTICALS INCORPORATED | 2021-04-15 | — | — | US | disclosed |
| US-20210107867-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACADEMIC PHARMACEUTICALS INCORPORATED | 2021-04-15 | — | — | US | disclosed |
| US-10793519-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INCORPORATED (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793519-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INCORPORATED (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190352257-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACADEMIC PHARMACEUTICALS INCORPORATED | 2019-11-21 | — | — | US | disclosed |
| US-20190352257-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACADEMIC PHARMACEUTICALS INCORPORATED | 2019-11-21 | — | — | US | disclosed |
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997037646-A1 | CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| US-4753962-A | HYPOGLYCEMIC, ANTIOBESITY AGENT | BEECHAM GROUP P.L.C. (GB) | 1988-06-28 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| US-4473566-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-25 | — | — | US | disclosed |
| US-4254117-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
| US-4143166-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352257-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | SCN5A, CACNA1G, CACNA1H | MAOB 2237/4885CYP19A1 3438/4885BRD4 2897/4885 |
| US-20210107867-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | SCN5A, CACNA1G, CACNA1H | MAOB 2237/4885CYP19A1 3438/4885BRD4 2897/4885 |
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | SCN5A, CACNA1G, CACNA1H | MAOB 2237/4885CYP19A1 3438/4885BRD4 2897/4885 |
| US-10793519-B2 | Ultra short acting anti-arrhythmic agents | SCN5A, CACNA1G, CACNA1H | MAOB 2237/4885CYP19A1 3438/4885BRD4 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.